APPLAUSE-IgAN
2025
Iptacopan in Primary IgA Nephropathy
In 250 patients with IgA nephropathy and persistent proteinuria, the factor-B inhibitor iptacopan reduced proteinuria compared with placebo.
Result
Primary endpoint: Reduction in 24-hour UPCR (month-9 interim); annualised eGFR slope
38.3% greater UPCR reduction versus placebo (p<0.0001); 2-year data met the eGFR-slope endpoint.
- Subtopic
- IgA nephropathy
- Design
- Phase 3 double-blind RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Perkovic V, et al. N Engl J Med. 2025;392(6):531-543.doi 10.1056/NEJMoa2410316
Discussion & critique
First complement factor-B inhibitor for IgA nephropathy; accelerated FDA approval of Fabhalta in 2024.